12 stories mentioning HKG:2335Updated 9d ago
Every FINWIRES story that references HKG:2335, newest first.
Shaanxi Micot Pharmaceutical Technology (HKG:2335) said its H shares have been included in the eligible securities lists under the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs, effective Monday, according to same-day Hong Kong bourse filing.The inclusion allows eligible mainland Chinese investors to trade the company's shares through the Shanghai Stock Exchange and Shenzhen Stock Exchange.
Shaanxi Micot Pharmaceutical Technology (HKG:2335) concluded the phase II clinical trial of MT200605 for the treatment of AIS, according to a Wednesday Hong Kong bourse filing.Shares of the Chinese biotechnology company were up nearly 2% in Thursday afternoon trading.The trial demonstrated significant and robust efficacy advantages with a favorable safety profile.
Shaanxi Micot Pharmaceutical Technology (HKG:2335) will be added to the Hang Seng Composite Index from Sept. 7, according to a Monday Hong Kong bourse filing.The shares are also expected to meet the eligibility criteria for trading through the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect.
Shaanxi Micot Pharmaceutical Technology's (HKG:2335) research results for XTL6001 have been accepted for presentation at multiple academic conferences in the fields of diabetes, metabolic diseases, and nephrology.Following an initial presentation at the American Diabetes Association, additional analysis will be presented at the upcoming European Association for the Study of Diabetes (EASD) and American Society of Nephrology (ASN) annual meetings, according to a Monday Hong Kong bourse filing.Two research abstracts will be featured at the 62nd annual meeting of the EASD, with one to be presented at ASN Kidney Week 2026.
Shaanxi Micot Pharmaceutical Technology's (HKG:2335) phase II clinical trial of MT200605 for the treatment of AIS obtained top-line results, according to a Monday Hong Kong bourse filing.Shares of the company were nearly 3% in Tuesday afternoon trading.Results showed that the study reached its primary endpoint with statistically significant and clinically meaningful outcomes, with the drug showing a favorable efficacy trend and safety and tolerability profile.
Shaanxi Micot Pharmaceutical Technology (HKG:2335) enrolled the first patient in a phase II clinical study of its MT1002.The drug is being tested for anticoagulation in HD patients, according to a Thursday Hong Kong bourse filing.
Shaanxi Micot Pharmaceutical Technology (HKG:2335) enrolled the first patient in a phase Ib/II clinical trial of MT1002.The drug is being tested for the treatment of acute ischemic stroke, according to a Friday Hong Kong bourse filing.
Hong Kong stocks rebounded Wednesday as investors looked past volatility in AI-related shares and focused on signs of progress in U.S.-Iran peace talks.The Hang Seng Index rose 0.3%, or 75.90 points, to close at 23,412.18, while the Hang Seng China Enterprises Index edged up 5.61 points to finish at 7,764.97.A sharp selloff in semiconductor stocks dragged the Nasdaq and S&P 500 to one-week lows Tuesday amid concerns over AI spending and a more hawkish Fed.Meanwhile, U.S. President Donald Trump said Tuesday that Iran had agreed to allow nuclear inspections indefinitely, a claim Tehran rejected, saying no such concession had been made in ongoing negotiations.The two sides, which concluded a first round of talks in Switzerland on Monday, also offered conflicting accounts on key elements of the framework agreement reached last week.In corporate news, two companies made their trading debut on the Hong Kong bourse.Shanghai Seer Intelligent Technology (HKG:6106) closed 4% higher at HK$106.00, compared with the offer price of HK$101.60.Shaanxi Micot Pharmaceutical Technology (HKG:2335) advanced 103% to close at HK$36.90, versus its offer price of HK$18.20.
Shaanxi Micot Pharmaceutical Technology (HKG:2335) raised HK$989.3 million in net proceeds from its initial public offering in Hong Kong, according to a Tuesday after-market filing with the Hong Kong Exchange.The biotechnology company priced its IPO at HK$18.20 per share, issuing 58.05 million shares.The Hong Kong public offering portion of the deal was 1,181.46 times subscribed, resulting in a final allocation of 5.8 million shares.The international offering was 2.52 times subscribed, with 52.2 million shares allocated.Cornerstone investors were allotted 24.68 million shares, representing 42.51% of the IPO shares.Micot Pharma is set to debut on the Hong Kong bourse today, June 24.
Shaanxi Micot Pharmaceutical Technology's (HKG:2335) shares opened 87% above their initial public offering price in a solid Hong Kong debut on Wednesday morning.The biotechnology company opened at HK$34.02 per share, well above the offer price of HK$18.20.
Hong Kong stocks began the week marginally higher as markets reacted to news of Iran and the U.S. reaching a preliminary deal to end hostilities and reopen the critical Strait of Hormuz.The Hang Seng Index rose by around 124.57 points, or roughly 0.5%, to end at 24,842.67, while the Hang Seng China Enterprises Index finished near flat, inching up 1.31 points, or 0.02%.U.S. President Donald Trump said on Truth Social on Monday that the deal with Iran would keep the Strait of Hormuz permanently open "toll-free" to shipping. He also authorized the immediate removal of the U.S. naval blockade from the key waterway.In local development, Hong Kong's index of industrial production for manufacturing industries increased 3.1% year over year in the first quarter of 2026, but was below the 5.8% expansion recorded in the previous quarter.By major sector, output volume was driven by a 6.6% rise in the metal, computer, electronic and optical products, machinery and equipment industry, while the food, beverages and tobacco sector grew by 2.1%.Elsewhere, the Chamber of Hong Kong Listed Companies urged regulators to further ease listing requirements for innovative companies, saying that lower barriers would help attract more technology firms to raise capital in the city, the South China Morning Post reported, citing comments from its chairman, Chan Ka-keung.In corporate news, two Chinese firms filed to go public in Hong Kong.Shaanxi Micot Pharmaceutical Technology (HKG:2335) said it was seeking HK$1.22 billion via the sale of 58.1 million H shares at an indicative maximum price of HK$21.00 per share. The biotechnology firm is raising funds to advance clinical development of its drug candidates.Meanwhile, Shanghai Seer Intelligent Technology (HKG:6106) is targeting as much as HK$1.07 billion with its offering of 10.5 million H shares at an indicative price of HK$101.60 per share. The robotics company will use proceeds to advance its technology and infrastructure.
Shaanxi Micot Pharmaceutical Technology (HKG:2335) launched its Hong Kong initial public offering on Monday, seeking to raise up to HK$1.22 billion.The Chinese biotechnology company is offering 58.1 million H shares at an indicative maximum price of HK$21.00 per share, according to a Hong Kong bourse filing.The offering comprises 5.8 million shares for Hong Kong investors and 52.2 million shares for international investors, subject to reallocation and the over-allotment option.The offer price is expected to be determined by June 18, with allocation results due by June 23, ahead of the company's planned trading debut on June 24.Net proceeds, estimated at HK$1.07 billion, will be used primarily to fund the ongoing and planned clinical development and commercialization of Micot Pharmaceutical's core and key product candidates.The company also plans to use the funds for the research and development of other pipeline candidates and technology platforms, as well as for working capital and general corporate purposes.CCB International Capital and China Merchants Securities (HK) are acting as joint sponsors, sponsor-overall coordinators, overall coordinators, joint global coordinators, joint bookrunners, and joint lead managers.
